TY - JOUR
T1 - Addressing the role of edaravone in the management of amyotrophic lateral sclerosis and gaps in care and access
T2 - Expert panel recommendations
AU - Barrington, Christina J.
AU - Burruano, Martin
AU - Carney, Caroline
AU - Choi, Joseph
AU - Januska, Jeff
AU - Lachuk, Lester
AU - Oskarsson, Björn
AU - Rodriguez, Carly
AU - Speicher, Lindsay
AU - Tereso, Gary
N1 - Funding Information:
Health, Buffalo, NY (MB); Magellan Health, Scottsdale, AZ (CC); Georgetown University Medical, Washington, DC (JC); CenCal Health, Santa Barbara, CA (JJ); BlueCross BlueShield of Western New York, Buffalo, NY (LL); Mayo Clinic, Jacksonville, FL (BO); Moda Health, Portland, OR (CR); Magellan Rx Management, Middletown, RI (LS); Health New England, Springfield, MA (GT) Funding source: Financial support for this work was provided by Mitsubishi Tanabe Pharmaceuticals and facilitated by Magellan Rx Management.
Publisher Copyright:
© 2021 Ascend Media. All rights reserved.
PY - 2021/8
Y1 - 2021/8
N2 - A virtual key opinion leader (KOL) and payer discussion was held on December 5, 2020. In attendance were 2 KOLs, both specialists in amyotrophic lateral sclerosis (ALS) at leading clinics in the United States, and 6 managed care executives from US regional health plans. The objective of this panel was to share opinions, ideas, and information around the treatment of ALS with edaravone, gaps in management and guidelines, and potential solutions. The panel concluded that coverage criteria for edaravone may need to be reassessed and treatment guidelines could be revisited to include a determination of place in therapy for edaravone.
AB - A virtual key opinion leader (KOL) and payer discussion was held on December 5, 2020. In attendance were 2 KOLs, both specialists in amyotrophic lateral sclerosis (ALS) at leading clinics in the United States, and 6 managed care executives from US regional health plans. The objective of this panel was to share opinions, ideas, and information around the treatment of ALS with edaravone, gaps in management and guidelines, and potential solutions. The panel concluded that coverage criteria for edaravone may need to be reassessed and treatment guidelines could be revisited to include a determination of place in therapy for edaravone.
UR - http://www.scopus.com/inward/record.url?scp=85113882870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113882870&partnerID=8YFLogxK
U2 - 10.37765/AJMC.2021.88732
DO - 10.37765/AJMC.2021.88732
M3 - Article
C2 - 34382759
AN - SCOPUS:85113882870
SN - 1088-0224
VL - 27
SP - S231-S237
JO - American Journal of Managed Care
JF - American Journal of Managed Care
IS - 12
ER -